free web stats
  • Developing new drugs to treat

    Shingles Pain

    ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies.

    Our lead candidate is FV-100, a potent oral antiviral being developed for the treatment of herpes zoster, commonly known as shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent than current FDA-approved drugs.

    About ContraVir Drug Development Programs
    Shingles Pain

About FV-100

FV-100 is a potent antiviral with rapid onset that could reduce nerve inflammation and ultimately pain in patients with herpes zoster, the late-term reactivation of the varicella-zoster virus (VZV).

Learn More
Proven Leadership

Proven Leadership

Management with proven track record in drug development.

Clear Regulatory Path

Clear Regulatory Path

Well-established FDA path and clear registration options.

Phase 2 Asset

Phase 2 Asset

Well tolerated Phase 2b asset for a significant unmet medical need.

Seeking Effective Shingles Relief

There are over 4 million cases of shingles in the U.S., Europe and Japan each year.

Herpes zoster, also commonly known as shingles, is a neurological disorder caused by the reactivation of varicella zoster virus (VZV), the same virus that causes chickenpox. We believe the opportunity exists for new products with better efficacy, safety, and more convenient dosing with the added advantages of reducing pain and the incidence of post-herpetic neuralgia.

The Opportunity